Prevalence of Vitamin D & Renal Dysfunction in Metabolic Syndrome
Background: Chronic kidney disease (CKD) is characterized by a progressive loss of renal function that often leads to end-stage renal disease (ESRD), high risk for cardiovascular disease, and high mortality [1,2]. CKD is a growing global health problem due to increased prevalence worldwide. In the United States, the prevalence of CKD was estimated to be 11% based on data from the Third National Health and Nutrition Examination Survey (NHANES III).
Methods: The case control study was carried out in the Departments of Biochemistry and Medicine of Heritage institute of Medical Sciences Varanasi. Duration of this study was six month.
Results: Twenty five patients each of hypovitaminosis & have chronic kidney disease in age group 31-60 years were included as cases. The prevalence of vitamin D status was low in control group as well as case group.
Conclusion: Treatment with active vitamin D or its analogues shows Reno protective effects by preventing fibrosis, apoptosis, and inflammation in various experimental models. Furthermore, vitamin D deficiency or insufficiency is a common condition in pre-dialysis or dialysis patients with CKD, and serum levels of vitamin D appear to be inversely correlated with kidney function.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-S266.
3. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
4. Shin SY, Kwon MJ, Park H, Woo HY. Comparison of chronic kidney disease prevalence examined by the chronic kidney disease epidemiology collaboration equation with that by the modification of diet in renal disease equation in Korean adult population. J Clin Lab Anal 2014 Feb 27 [Epub]. http://dx.doi.org/10.1002/ jcla.21688.
5. Ruilope LM. Renal function and cardiovascular risk in hypertensive patients. J Hypertens 2005;23:1787-1788.
6. Holick MF. Vitamin D def iciency. N Engl J Med 2007;357:266-281.
7. LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am
J Kidney Dis 2005;45:1026-1033.
8. Urena-Torres P, Metzger M, Haymann JP, et al. Association of kidney
function, vitamin D deficiency, and circulating markers of mineral and
bone disorders in CKD. Am J Kidney Dis 2011;58:544-553.
9. Mehrotra R, Kermah DA, Salusky IB, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int
10. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status
and mortality risk in CKD: a meta-analysis of prospective studies. Am J
Kidney Dis 2011;58:374-382.
11. Zheng Z, Shi H, Jia J, Li D, Lin S. Vitamin D supplementation and
mortality risk in chronic kidney disease: a meta-analysis of 20
observational studies. BMC Nephrol 2013;14:199.
12. Doorenbos CR, van den Born J, Navis G, de Borst MH. Possible
renoprotection by vitamin D in chronic renal disease: beyond mineral
metabolism. Nat Rev Nephrol. 2009; 5: 691-700.
13. Jones G. Expanding role for vitamin D in chronic kidney disease:
importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin Dial. 2007; 20: 316-24.
14. Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int. 2011; 79: 715-29.
15. Wang XX, Jiang T, Shen Y, Caldas Y, Miyazaki-Anzai S, Santamaria H, et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes. 2010; 59: 2916-27.
16. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006; 69: 33-43.
17. Ma J, Zhang B, Liu S, Xie S, Yang Y, Ma J, et al. 1,25-dihydroxyvitamin
D(3) inhibits podocyte uPAR expression and reduces proteinuria. PLoS
One. 2013; 8: e64912.
18. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, et al.
Renoprotective role of the vitamin D receptor in diabetic nephropathy.
Kidney Int. 2008; 73: 163-71.
19. Zou MS, Yu J, Nie GM, He WS, Luo LM, Xu HT. 1, 25-dihydroxyvitamin
D3 decreases adriamycin-induced podocyte apoptosis and loss. Int J
Med Sci. 2010; 7: 290-9.
21. LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, et al.
Prevalence of calcidiol deficiency in CKD: a cross-sectional study across
latitudes in the United States. Am J Kidney Dis. 2005; 45: 1026-33.
22. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate
early kidney disease. Kidney Int. 2007; 71: 31-8.
et al. High prevalence of vitamin D insufficiency and its association with BMI-for-age among primary school children in Kuala Lumpur, Malaysia. BMC Publ Health 2011;11:95.
24. Rahman SA, Chee WSS, Yassin Z, Chan SP. Vitamin D status among postmenopausal Malaysian women. Asia Pac J Clin Nutr 2004;13:255- 60.
25. RossAC,MansonJE,AbramsSA,AloiaJF,BrannonPM,ClintonSKet al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-8.
26. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R et al. Prevalence of cardiovascular risk factors and the serum levels of 25- hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2007;167:1159-65.
27. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80(6 Suppl): 1678S-88S.
28. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71:31-8.
Saliba W, Rennert HS, Kershenbaum A, Rennert G. Serum 25(OH)D concentrations in sunny Israel. Osteoporos Int 2012;23: 687-94.
30. Sedrani SH. Low 25-hydroxyvitamin D and normal serum calcium concentrations in Saudi Arabia: Riyadh region. Ann Nutr Metab 1984;28:181-5.
31. Lowe NM, Mitra SR, Foster PC, Bhojani I, McCann JF. Vitamin D status and markers of bone turnover in Caucasian and South Asian postmenopausal women living in the UK. Br J Nutr 2010;103:1706-10.
32. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL et al. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1144-51.
Martin T, Campbell RK. Vitamin D and diabetes. Diabetes Spectrum 2011;24:113-8.
34. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
35. González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency
and deficiency in chronic kidney disease. A single center observational
study. Am J Nephrol 2004;24:503-10.
36. Gal-Moscovici A, Sprague SM. Role of vitamin D deficiency in chronic
kidney disease. J Bone Miner Res 2007;22(Suppl2):V91-4.
37. Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL. Vitamins K and D status in stages 3-5 chronic kidney disease. Clin J Am
Soc Nephrol 2010;5:590-7.
Copyright (c) 2018 International Archives of BioMedical and Clinical Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.